Browsing: Pharma

Outlook Therapeutics has won the difficult battle to commercialize the ophthalmic version of Roche’s Avastin…

Explore the key challenges in drug discovery for 2026, including AI integration, regulatory hurdles, and precision medicine trends affecting biopharma pipelines.

Healthcare and life sciences companies face tremendous pressure to remain profitable amid turbulent regulatory, pricing…

Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary…

A multibillion-dollar acquisition in the radiopharmaceutical space could be on the horizon, as Lantheus Holding…

More than three years after Gilead Sciences’ hepatitis D drug brevirtide was rejected by the…

Author: Guy Amster, Senior Principal Machine Learning Engineer, Flatiron HealthReal-world evidence (RWE) has long held…

The battle for TROP2 in first-line triple-negative breast cancer has officially begun. On Friday, Daiichi…

Two major pharmaceutical companies are cutting U.S. jobs this summer, with Novartis telegraphing 76 more…

同社は昨年、現場のアラガン専門の従業員を202人削減したが、これは「ダイナミックなエステティック業界内で持続的なリーダーシップを発揮するため、アラガン・エステティックスをより良い位置に置くための組織再編」を反映した措置であると同社の広報担当者は当時フィアース・ファーマに語った。 Before that, there were 99 layoffs in 2022. Source link